vida: extract claims from 2025-05-31-oma-asn-aclm-obesity-society-glp1-nutritional-priorities-advisory

- Source: inbox/queue/2025-05-31-oma-asn-aclm-obesity-society-glp1-nutritional-priorities-advisory.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 1
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp-1-nutritional-support-advisory-recommends-snap-enrollment-creating-institutional-contradiction-with-snap-cuts.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: Four major medical societies identify food assistance as necessary infrastructure for GLP-1 therapy while Congress cuts the same programs by 186 billion through 2034
+confidence: experimental
+source: OMA/ASN/ACLM/Obesity Society joint advisory SNAP recommendation, OBBBA SNAP cuts
+created: 2026-04-11
+title: GLP-1 nutritional support advisory explicitly recommends SNAP enrollment support creating institutional contradiction with simultaneous 186 billion dollar SNAP cuts
+agent: vida
+scope: structural
+sourcer: OMA/ASN/ACLM/Obesity Society
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
+---
+
+# GLP-1 nutritional support advisory explicitly recommends SNAP enrollment support creating institutional contradiction with simultaneous 186 billion dollar SNAP cuts
+
+The joint advisory from OMA, ASN, ACLM, and The Obesity Society explicitly identifies food insecurity and nutrition insecurity as barriers to equitable obesity management with GLP-1s. The screening checklist includes food insecurity, nutrition insecurity, and housing/transportation challenges. The advisory recommends 'eligibility assessment and enrollment support (if eligible) for federal food assistance programs such as SNAP' as part of standard GLP-1 therapy support. This is not peripheral guidance but core to the nutritional priorities framework: GLP-1 therapy requires nutrient-dense, minimally processed diets (80-120g protein/day, multiple micronutrients) while simultaneously suppressing appetite, making food quality critical when food quantity is reduced. The advisory cites evidence that group-based models showed greater weight reduction in majority Latino and low-income households in federally-designated underserved areas, suggesting that nutritional support infrastructure improves outcomes. However, this clinical guidance was published in May/June 2025, the same period as the OBBBA SNAP cuts of 186 billion dollars through 2034. The institutional contradiction is explicit: medical societies identify SNAP as necessary infrastructure for a therapy projected to reach tens of millions of users, while Congress simultaneously cuts access to that infrastructure. This is not a policy debate about SNAP's general value but a direct conflict between healthcare innovation requirements and food policy implementation.

domains/health/glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: The appetite suppression mechanism that drives GLP-1 efficacy creates micronutrient deficiency risk requiring dietitian monitoring, but implementation data shows the infrastructure does not exist
+confidence: experimental
+source: "OMA/ASN/ACLM/Obesity Society joint advisory, 92% no dietitian contact finding"
+created: 2026-04-11
+title: GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales
+agent: vida
+scope: structural
+sourcer: OMA/ASN/ACLM/Obesity Society
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
+---
+
+# GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales
+
+GLP-1 receptor agonists suppress appetite as their primary mechanism, reducing caloric intake by 20-30%. This creates systematic micronutrient deficiency risk across iron, calcium, magnesium, zinc, and vitamins A, D, E, K, B1, B12, and C. The joint advisory from four major obesity/nutrition organizations identifies protein intake as 'difficult to achieve' during active weight loss, requiring 1.2-1.6 g/kg/day (versus 0.8 baseline) to preserve lean mass. However, implementation data shows 92% of GLP-1 patients had NO dietitian visit in the 6 months prior to prescription. Only 8.3% had dietitian contact in the 180 days before treatment initiation. This creates a structural care gap: the therapy's mechanism requires continuous nutritional monitoring, but the delivery infrastructure does not exist. As GLP-1 adoption scales from current millions to projected tens of millions of users, this gap widens arithmetically. The advisory recommends regular food logs, nutrient level lab testing (B12, 25(OH)D, iron, folic acid), and body composition monitoring (BIA, DXA) — none of which occur in standard primary care workflows. This is not a temporary implementation lag but a structural mismatch between the therapy's continuous-treatment model and the episodic-care delivery system.